Sunday, March 12, 2017 2:22:23 PM
The share price thing is really all conjecture. And the history of this company isn't great.
For me right now I would very much like to see baby steps, meaning lets see if the FDA overturns there original denial of Macrilen. Which they will only do if they agree that there is enough positive evidence of this drugs capabilities while over looking the fact that it narrowly missed an end point. Believing there is enough good with the ease of testing the safety compared to the ITT and results of test that are as good or better than the ITT. I feel if the first domino falls in the way of the company giving them a real revenue stream then it will be easier for the next domino to fall there way.
Just my two cents. Obviously we all know that Zoptrex has the much, much higher ceiling and the FDA seems to really like safety, and the fact that this appears to have a great safety profile it could help along with gov't supposedly looking to ease approvals.
As far as dilution I personally hope that if Zoptrex does pass the European company that AEZS is supposedly in negotiations with will supply an upfront payment large enough to fund bringing both products to market. Whether that is a likely scenario I don't know. But the company did say they were in negotiations and wanted to wait for results as it would put them in a stronger position.
Of course it could all the wrong way and we're all phucked. except for the nay sayers and shorters who will be in full force saying I told you so. Either way we will know within 30-60 days the whole truth of it.
Fingers crossed
Recent CSCI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 11:30:23 AM
- COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs • GlobeNewswire Inc. • 09/23/2024 11:30:00 AM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM